logo
Sign in

REVERAGEN BIOPHARMA, INC.

Rockville, MD · Biotech · Private

Vamorolone, a dissociative steroidal molecule for treating Duchenne muscular dystrophy

Claim this profile

Follows are private to you and power your alerts

Updated

Sector
Biotech
Headquarters
Rockville, MD
Latest Form D
$800K, Mar 2018
Total capital
$13M
Federal grants
$12.2M
11 awards · 2015–2020
Rank in peer group#34 of 514
Private capital raised
$800K
1 Form D · last Mar 2018
104 months since last filing
Federal contracts
None on recordNo federal contract awards found.
Granted patents
12
28 pending · first 2016
Rank in peer group#23 of 514

Capital timeline

201520162017201820192020FEDERAL ↑EQUITY ↓Cumulative $13M$1.5M$254K$1.5M$3.1M$1.5M$3.4M1st Form D$800K
201520162017201820192020FEDERAL ↑EQUITY ↓Cumulative $13M$1.5M$3.1M$1.5M$3.4M1st Form D$800K

Latest events

  • Federal grantHealth and Human S · Phase II · Commercialization Readiness Pilot (CRP) to maximize vamorolone international labeling and sales$3.4M
  • Federal grantHealth and Human S · Phase II · Pivotal trial of vamorolone in Duchenne muscular dystrophy$1.5M
  • Federal grantHealth and Human S · Phase II · Establishing a Cost-effective Return of Results to Parents of Boys in VISION-DMD Clinical Trials$110K
  • Federal grantHealth and Human S · Phase II · Pivotal trial of vamorolone in Duchenne muscular dystrophy$3.1M
  • Federal grantHealth and Human S · Phase I · Building an evidentiary case for circulating GHBP as a biomarker for drug-associated stunting of growth$225K
  • Federal grantHealth and Human S · Phase I · Definition of pharmacodynamic biomarkers for juvenile dermatomyositis for clinical trials$225K
  • Federal grantHealth and Human S · Phase I · Establishing a biomarker framework for feasibility studies of vamorolone in vasculitis$178K
  • Private capital raisedForm D · SEC · 1st filing$800K
Show 4 earlier federal awards
  • Federal grantHealth and Human S · Phase II · Phase IIa study of VBP15 for Duchenne muscular dystrophy$1.5M
  • Federal grantHealth and Human S · Phase I · Effectiveness of VBP15, a dissociative steroidal analogue, on chronic inflammation in a mouse model of multiple sclerosis$254K
  • Federal grantHealth and Human S · Phase II · Phase IIa study of VBP15 for Duchenne muscular dystrophy$1.5M
  • Federal grantHealth and Human S · Phase I · Effectiveness of VBP15, a dissociative steroidal analogue, on inflammation in a mouse model of arthritis$225K

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Federal first

30months

from REVERAGEN BIOPHARMA, INC.’s first federal award to its first private round.

First federal award · Sep 2015
Health and Human S · $225K
First Form D · Mar 2018
$800K · 1st Form D
Awards before first raise
4 awards

An association in public records, not a cause or a prediction.

Standing among 514 peers

Line = median

Biotech · Molecule

  • Federal grants#34 · top 7%
  • Granted patents#23 · top 4%
  • Linked publications#3 · top 1%

Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.

Founders and team

Researcher links verified by same-company patents and grants
  • John M. McCallResearcherExecutive Officer, DirectorLinked by 3 patents
  • Eric P. HoffmanResearcherExecutive Officer, DirectorLinked by $6.7M in grants as PI
  • Elizabeth A. SingerDirectorNamed in SEC Form D filings
  • Kanneboyina M. NagarajuExecutive Officer, DirectorNamed in SEC Form D filings
  • May P. LiangDirectorNamed in SEC Form D filings

What it has protected

USPTO · 12 granted of 40
  • PendingNon-hormonal Steroid Modulators Of Nf-kb For Treatment Of DiseaseUSPTOApplication 19656888
  • PendingAqueous Oral Pharmaceutical Suspension CompositionsUSPTOApplication 18975425
  • PendingNon-hormonal Steroid Modulators Of Nf-kappa Beta For Treatment Of DiseaseUSPTOApplication 19014902
Show all 40 patent records

Recent research by its founders

  • Mineralocorticoid receptor antagonism of vamorolone: Evidence from LIONHEART and VISION-DMD clinical trials20257 cites
  • The effect of IL-1β inhibitor canakinumab (Ilaris®) on IL-6 production in human skeletal muscle cells20256 cites
  • Association of <i>DMD</i> Gene Variant Classes With Motor Outcomes in a Drug Registration Clinical Trial Setting20254 cites

Related companies, and why

  • AyuVis Research, Inc.Similar federal contract value in Biotech · null in contracts
  • EPOCH BIOTECH, LLCSimilar federal contract value in Biotech · null in contracts
  • Galera Therapeutics Inc.Similar federal contract value in Biotech · null in contracts
  • SCARLESS LABORATORIES INCSimilar federal contract value in Biotech · null in contracts
  • Nymirum, Inc.Similar federal contract value in Biotech · null in contracts
  • Covira SurgicalSimilar federal contract value in Biotech · null in contracts

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through . SBIR and STTR awards through .